Interest in cannabidiol (CBD) has taken off over the past five years since CNN highlighted its promise in the documentary Weed. GW Pharma (NASDAQ: GWPH) has submitted a New Drug Application for its CBD-based Epidiolex (which has received Orphan Drug Status in the European Union) with the FDA.
If it receives final approval later this year (which appears probable) it would be the first pharmaceutical ever legally available that was derived from botanical cannabis, sparking even more interest in CBD. The Hemp Business Journal believes that the market for CBD derived from industrial hemp will grow from approximately $50 million in 2014 to upwards of $736 million in 2020.
With so much interest in CBD, and bigger companies starting to make investments in the sector, what should a cautious investor look for to help make an informed decision in this emerging market? Here are a few filters to apply when evaluating CBD producers before investing:
- Does the company file with the SEC? Transparency is a must for investors. If there are no filings, then the company isn’t truly transparent.
- Next, does the company generate significant revenue?
- In addition, the company should clearly explain the source of its CBD and the methods of production? CBD can be produced in a variety of ways, including both naturally and synthetically. Synthetic CBD may prove to be more economical in the long term if it is as efficacious as plant-derived CBD, but it’s too early to make that call.
- Finally, one should know if there are any sort of independent evaluations or reviews of the company’s products?
You may be interested
Cash Crop Today Interview with CEO of Open Grow™ João MeloEditor - September 25, 2018
Open Grow™ is a company located in Portugal that is dedicated to the research and creation of automation solutions for the agricultural growing environments. Their company aims to…
Lender420 Provides Funding Solutions to Fit Your Company’s Equipment NeedsEditor - September 24, 2018
Purchasing equipment involved in the cultivation, processing, manufacturing, and distribution of the cannabinoid-derived products can be one of the most expensive costs of setting up a successful…
Elixinol Global to increase ownership in Elixinol Japan to 50.5%Editor - September 24, 2018
Public company Elixinol Global Limited (ASX: EXL; OTCQX: ELLXF), a prominent producer of industrial hemp derived CBD products announced yesterday that its wholly-owned subsidiary, EXL International Holdings,…